| 摘要 |
PCT No. PCT/DE88/00151 Sec. 371 Date Nov. 23, 1988 Sec. 102(e) Date Nov. 23, 1988 PCT Filed Mar. 11, 1988 PCT Pub. No. WO88/07037 PCT Pub. Date Sep. 22, 1988.The invention relates to 6-oxo-prostaglandin E1 derivatives of formula I, <IMAGE> (I) in which R1 means the radical COOR2 with R2 meaning a hydrogen atom, C1-C10 alkyl, a C5-C6 cycloalkyl or a C6-C10 aryl group or a heterocyclic radical, or the radical CONHSO2 R5 as C1-10 alkyl, C5-6 cycloalkyl or C6-10 aryl, A means an E-configuration CH=CH or a -C=C group, W means a free or functionally modified hydroxymethylene group or a free or functionally modified group, and the OH group in each case can be in the alpha or beta position, D means a straight-chain or branched-chain alkylene group with 1-5 C atoms, E means a -C=C group or a C2-C4 alkenylene group, R3 means C1-C10 alkyl, C3-C10 cycloalkyl or an optionally substituted C6-C10 aryl group or a heterocyclic group, R4 means a free or functionally modified hydroxy group, and if R2 means a hydrogen atom, its salts with physiologically compatible bases as well as alpha, beta or gamma cyclodextrin clathrates of the compounds of formula I, process for their production and their pharmaceutical use. |
